MedTrace Logo

Immunomodulation Effect of Blood Transfusion

NCT02140216 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-09-08

No results posted yet for this study

Summary

An increasing number of publications have demonstrated that homologous (allogeneic) blood transfusion impairs outcome in cancer and non-cancer patients. Leukocyte depletion of blood products cannot solve these problems, despite improved quality of red cells; a recent study demonstrated deteriorated outcome of cancer patients with elective colon surgery and transfusion of leukocyte depleted allogeneic blood.

Conditions

  • Incompatible Blood Transfusion
  • Immune Defect
  • Surgery

Interventions

BIOLOGICAL

No blood transfusion

No blood transfusion

BIOLOGICAL

Day 0 blood transfusion

Patients undergoing elective spine surgery receiving intra- or immediate-postoperative red cell blood transfusion.

BIOLOGICAL

Day 1 or 2 blood transfusion

Patients undergoing elective spine surgery receiving first red cell blood transfusion on day 1 or 2 after surgery.

Sponsors & Collaborators

  • Wolf Schleinzer Stiftung zur Wissenschafts- und Bildungsförderung, Germany

    collaborator UNKNOWN

  • Mahidol University

    lead OTHER

Principal Investigators

  • Sirilak Suksompong, MD · Mahidol University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2017-06-18
Completion
2018-04-10

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02140216 on ClinicalTrials.gov